A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics.
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.